{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:30:33Z","timestamp":1786984233437,"version":"build-2736575974"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010754","name":"National Healthcare Group","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010754","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/TCR\/003\/2008"],"award-info":[{"award-number":["NMRC\/TCR\/003\/2008"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["NMRC\/NIG\/1017\/2010"],"award-info":[{"award-number":["NMRC\/NIG\/1017\/2010"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001350","name":"Ministry of Health -Singapore","doi-asserted-by":"publisher","award":["MOH-000013"],"award-info":[{"award-number":["MOH-000013"]}],"id":[{"id":"10.13039\/501100001350","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Asian Journal of Psychiatry"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.ajp.2022.103192","type":"journal-article","created":{"date-parts":[[2022,6,18]],"date-time":"2022-06-18T02:01:09Z","timestamp":1655517669000},"page":"103192","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Metabolic syndrome and cardiovascular risk between clozapine and non-clozapine antipsychotic users with schizophrenia"],"prefix":"10.1016","volume":"74","author":[{"given":"Yue Feng","family":"Quek","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen Mei","family":"See","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie Yin","family":"Yee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gurpreet","family":"Rekhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boon Tat","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charmaine","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ajp.2022.103192_bib1","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1111\/j.1464-5491.2006.01858.x","article-title":"Metabolic syndrome\u2014a new world-wide definition. A consensus statement from the International Diabetes Federation","volume":"23","author":"Alberti","year":"2006","journal-title":"Diabet. Med."},{"issue":"4","key":"10.1016\/j.ajp.2022.103192_bib2","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1192\/pb.21.4.224","article-title":"Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications","volume":"21","author":"Atkins","year":"1997","journal-title":"Psychiatr. Bull."},{"issue":"4","key":"10.1016\/j.ajp.2022.103192_bib3","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0094112","article-title":"Almost all antipsychotics result in weight gain: a meta-analysis","volume":"9","author":"Bak","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.ajp.2022.103192_bib4","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1037\/a0031228","article-title":"Antipsychotic polypharmacy increases metabolic dysregulation in female rats","volume":"21","author":"Boyda","year":"2013","journal-title":"Exp. Clin. Psychopharmacol."},{"issue":"6","key":"10.1016\/j.ajp.2022.103192_bib5","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.pnpbp.2010.04.024","article-title":"A parametric study of the acute effects of antipsychotic drugs on glucose sensitivity in an animal model","volume":"34","author":"Boyda","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.ajp.2022.103192_bib6","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1186\/s12888-016-1121-1","article-title":"Cardiometabolic health, prescribed antipsychotics and health-related quality of life in people with schizophrenia-spectrum disorders: a cross-sectional study","volume":"16","author":"Bressington","year":"2016","journal-title":"BMC Psychiatry"},{"issue":"1","key":"10.1016\/j.ajp.2022.103192_bib7","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1186\/s12875-020-01316-5","article-title":"Attitudes to physical healthcare in severe mental illness; a patient and mental health clinician qualitative interview study","volume":"21","author":"Butler","year":"2020","journal-title":"BMC Fam. Pract."},{"issue":"2","key":"10.1016\/j.ajp.2022.103192_bib8","first-page":"96","article-title":"Agranulocytosis monitoring with clozapine patients: to follow guidelines or to attempt therapeutic controversies?","volume":"49","author":"Chandrasekaran","year":"2008","journal-title":"Singap. Med. J."},{"issue":"3","key":"10.1016\/j.ajp.2022.103192_bib9","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/acps.12989","article-title":"Clozapine and all-cause mortality in treatment-resistant schizophrenia: a historical cohort study","volume":"139","author":"Cho","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"issue":"9403","key":"10.1016\/j.ajp.2022.103192_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0140-6736(03)15268-3","article-title":"Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies","volume":"363","author":"Consultation","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.ajp.2022.103192_bib11","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1161\/CIRCULATIONAHA.107.699579","article-title":"General cardiovascular risk profile for use in primary care","volume":"117","author":"D\u2019Agostino","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ajp.2022.103192_bib12","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0022-3956(74)90071-5","article-title":"Dose equivalence of the anti-psychotic drugs","volume":"11","author":"Davis","year":"1974","journal-title":"J. Psychiatr. Res."},{"issue":"2","key":"10.1016\/j.ajp.2022.103192_bib13","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1038\/nrendo.2011.156","article-title":"Metabolic and cardiovascular adverse effects associated with antipsychotic drugs","volume":"8","author":"De Hert","year":"2011","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.ajp.2022.103192_bib14","doi-asserted-by":"crossref","first-page":"339","DOI":"10.3109\/08039488.2014.983544","article-title":"Clozapine use and sedentary lifestyle as determinants of metabolic syndrome in outpatients with schizophrenia","volume":"69","author":"Eskelinen","year":"2015","journal-title":"Nord. J. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103192_bib15","unstructured":"First, M.B., Spitzer, R.L., Gibson, M., Williams, J.B.W., 2002. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I\/P). Biometric Research, New York State Psychiatric Institute, New York."},{"issue":"9","key":"10.1016\/j.ajp.2022.103192_bib16","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1017\/S146114571100201X","article-title":"A systematic review of the evidence of clozapine\u2019s anti-aggressive effects","volume":"15","author":"Frogley","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.ajp.2022.103192_bib17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.schres.2012.03.018","article-title":"Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta-regression of global and regional trends from the 1970s to 2009","volume":"138","author":"Gallego","year":"2012","journal-title":"Schizophr. Res."},{"issue":"3","key":"10.1016\/j.ajp.2022.103192_bib18","doi-asserted-by":"crossref","first-page":"224","DOI":"10.4103\/0253-7176.183091","article-title":"Metabolic disturbances, side effect profile and effectiveness of clozapine in adolescents","volume":"38","author":"Grover","year":"2016","journal-title":"Indian J. Psychol. Med."},{"issue":"17","key":"10.1016\/j.ajp.2022.103192_bib19","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1161\/CIRCULATIONAHA.105.169404","article-title":"Diagnosis and management of the metabolic syndrome","volume":"112","author":"Grundy","year":"2005","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ajp.2022.103192_bib20","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.4088\/JCP.v66n0905","article-title":"Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study","volume":"66","author":"Henderson","year":"2005","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.ajp.2022.103192_bib21","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/0269881109102788","article-title":"The prevalence of undiagnosed metabolic abnormalities in people with serious mental illness","volume":"24","author":"Holt","year":"2010","journal-title":"J. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.ajp.2022.103192_bib22","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1176\/appi.ajp.2016.16050503","article-title":"Treatment-resistant schizophrenia: Treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology","volume":"174","author":"Howes","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103192_bib23","unstructured":"IBM Corp, 2015. IBM SPSS Statistics for Windows, Version 23.0. (23.0) [Computer software]."},{"issue":"2","key":"10.1016\/j.ajp.2022.103192_bib24","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3371\/CSRP.3.2.3","article-title":"An archival, follow-forward exploration of the metabolic syndrome in randomly selected, clozapine-treated patients","volume":"3","author":"Josiassen","year":"2009","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"2","key":"10.1016\/j.ajp.2022.103192_bib25","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","article-title":"The social and economic burden of treatment-resistant schizophrenia: a systematic literature review","volume":"29","author":"Kennedy","year":"2013","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.ajp.2022.103192_bib26","doi-asserted-by":"crossref","DOI":"10.4061\/2011\/931402","article-title":"Waist circumference, body mass index, and other measures of adiposity in predicting cardiovascular disease risk factors among Peruvian adults","volume":"2011","author":"Knowles","year":"2011","journal-title":"Int. J. Hypertens."},{"key":"10.1016\/j.ajp.2022.103192_bib27","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.schres.2018.02.035","article-title":"Cardio-metabolic risk and its management in a cohort of clozapine-treated outpatients","volume":"199","author":"Lappin","year":"2018","journal-title":"Schizophr. Res."},{"issue":"1","key":"10.1016\/j.ajp.2022.103192_bib28","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1146\/annurev-clinpsy-032813-153657","article-title":"Excess early mortality in schizophrenia","volume":"10","author":"Laursen","year":"2014","journal-title":"Annu. Rev. Clin. Psychol."},{"issue":"1","key":"10.1016\/j.ajp.2022.103192_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1176\/ajp.149.1.68","article-title":"Clozapine-induced weight gain: Prevalence and clinical relevance","volume":"149","author":"Leadbetter","year":"1992","journal-title":"Am. J. Psychiatry"},{"issue":"10","key":"10.1016\/j.ajp.2022.103192_bib30","doi-asserted-by":"crossref","first-page":"6","DOI":"10.47102\/annals-acadmedsg.V41N10p457","article-title":"Prevalence of metabolic syndrome among patients with schizophrenia in Singapore","volume":"41","author":"Lee","year":"2012","journal-title":"Ann. Acad. Med. Singap."},{"issue":"2","key":"10.1016\/j.ajp.2022.103192_bib31","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1093\/schbul\/sbu001","article-title":"Dose equivalents for second-generation antipsychotics: the minimum effective dose method","volume":"40","author":"Leucht","year":"2014","journal-title":"Schizophr. Bull."},{"issue":"1","key":"10.1016\/j.ajp.2022.103192_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1017\/ipm.2020.12","article-title":"Routine screening and rates of metabolic syndrome in patients treated with clozapine and long-acting injectable antipsychotic medications: a cross-sectional study","volume":"38","author":"Lydon","year":"2021","journal-title":"Ir. J. Psychol. Med."},{"issue":"4","key":"10.1016\/j.ajp.2022.103192_bib33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4103\/0971-5916.184284","article-title":"Lifestyle related factors & impact of metabolic syndrome on quality of life, level of functioning & self-esteem in patients with bipolar disorder & schizophrenia","volume":"143","author":"Malhotra","year":"2016","journal-title":"Indian J. Med. Res."},{"issue":"1","key":"10.1016\/j.ajp.2022.103192_bib34","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/1471-244X-11-118","article-title":"Is antipsychotic polypharmacy associated with metabolic syndrome even after adjustment for lifestyle effects?: a cross-sectional study","volume":"11","author":"Misawa","year":"2011","journal-title":"BMC Psychiatry"},{"issue":"S2","key":"10.1016\/j.ajp.2022.103192_bib35","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S0924-9338(10)71699-0","article-title":"The need for routine physical health care in schizophrenia","volume":"25","author":"Montejo","year":"2010","journal-title":"Eur. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103192_bib36","first-page":"9","article-title":"A longitudinal study of change in prevalence of metabolic syndrome and metabolic disturbances 3 months after clozapine therapy","volume":"18","author":"Nebhinani","year":"2013","journal-title":"J. Ment. Health Hum. Behav."},{"issue":"4","key":"10.1016\/j.ajp.2022.103192_bib37","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3371\/CSRP.KNMG.111717","article-title":"Clozapine, diabetes mellitus, cardiovascular risk and mortality: results of a 21-year naturalistic study in patients with schizophrenia and schizoaffective disorder","volume":"12","author":"Nemani","year":"2019","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"2","key":"10.1016\/j.ajp.2022.103192_bib38","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41569-020-00463-7","article-title":"Cardiovascular disease in patients with severe mental illness","volume":"18","author":"Nielsen","year":"2021","journal-title":"Nat. Rev. Cardiol."},{"issue":"5","key":"10.1016\/j.ajp.2022.103192_bib39","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1177\/2042018812458697","article-title":"Interventions for the metabolic syndrome in schizophrenia: a review","volume":"3","author":"Papanastasiou","year":"2012","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.ajp.2022.103192_bib40","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.genhosppsych.2016.09.005","article-title":"Estimating 10-year cardiovascular disease risk in Asian patients with schizophrenia","volume":"43","author":"Rekhi","year":"2016","journal-title":"Gen. Hosp. Psychiatry"},{"issue":"9","key":"10.1016\/j.ajp.2022.103192_bib41","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/14740338.2016.1191468","article-title":"Clozapine\u2019s critical role in treatment resistant schizophrenia: ensuring both safety and use","volume":"15","author":"Remington","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.ajp.2022.103192_bib42","doi-asserted-by":"crossref","first-page":"10767","DOI":"10.1038\/s41598-021-90188-5","article-title":"Agreement between laboratory-based and non-laboratory-based Framingham risk score in Southern Iran","volume":"11","author":"Rezaei","year":"2021","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.ajp.2022.103192_bib43","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1192\/bjp.bp.115.177261","article-title":"Clozapine v. First- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis","volume":"209","author":"Siskind","year":"2016","journal-title":"Br. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.ajp.2022.103192_bib44","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/070674370304800512","article-title":"Diabetes mellitus and impaired glucose tolerance in patients with schizophrenia","volume":"48","author":"Subramaniam","year":"2003","journal-title":"Can. J. Psychiatry"},{"issue":"1","key":"10.1016\/j.ajp.2022.103192_bib45","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/1039856216665282","article-title":"Metabolic monitoring and management among clozapine users","volume":"25","author":"Tso","year":"2017","journal-title":"Australas. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103192_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2021.102877","article-title":"Prevalence, clinical correlates and risk factors associated with Tardive Dyskinesia in Chinese patients with schizophrenia","volume":"66","author":"Uludag","year":"2021","journal-title":"Asian J. Psychiatry"},{"key":"10.1016\/j.ajp.2022.103192_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajp.2021.102742","article-title":"Patterns of antipsychotic prescriptions in patients with schizophrenia in China: a national survey","volume":"62","author":"Wang","year":"2021","journal-title":"Asian J. Psychiatry"},{"issue":"5","key":"10.1016\/j.ajp.2022.103192_bib48","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1017\/S2045796017000166","article-title":"Increased cardiovascular mortality in people with schizophrenia: a 24-year national register study","volume":"27","author":"Westman","year":"2018","journal-title":"Epidemiol. Psychiatr. Sci."}],"container-title":["Asian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201822001903?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1876201822001903?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T07:24:42Z","timestamp":1778829882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1876201822001903"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":48,"alternative-id":["S1876201822001903"],"URL":"https:\/\/doi.org\/10.1016\/j.ajp.2022.103192","relation":{},"ISSN":["1876-2018"],"issn-type":[{"value":"1876-2018","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metabolic syndrome and cardiovascular risk between clozapine and non-clozapine antipsychotic users with schizophrenia","name":"articletitle","label":"Article Title"},{"value":"Asian Journal of Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajp.2022.103192","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103192"}}